Difference between revisions of "Cemiplimab (Libtayo)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-monoclonal-antibody-regn2810 NCI Drug Dictionary]: A human monoclonal...") |
m |
||
| Line 4: | Line 4: | ||
=Preliminary data= | =Preliminary data= | ||
===[[Cutaneous squamous cell carcinoma]]=== | ===[[Cutaneous squamous cell carcinoma]]=== | ||
| − | + | * Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. Epub 2018 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1805131 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29863979 PubMed] | |
| − | carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. Epub 2018 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1805131 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29863979 PubMed] | ||
==Also known as== | ==Also known as== | ||
Revision as of 18:26, 7 August 2018
Mechanism of action
From NCI Drug Dictionary: A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways.
Preliminary data
Cutaneous squamous cell carcinoma
- Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. Epub 2018 Jun 4. link to original article PubMed
Also known as
- Code name: REGN2810